Targeting the alternatively spliced soluble isoform of CTLA-4

prospects for immunotherapy?

Frank J Ward, Lekh N Dahal, Rahul C Khanolkar, Sucharita P Shankar, Robert N Barker

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

CTLA-4 is an inhibitory protein that contributes to immune homeostasis and tolerance, a role that has led to its exploitation as a therapeutic in several clinical settings including cancer and autoimmune disease. Development of CTLA-4 therapies focused largely on the full-length receptor isoform but other CTLA-4 isoforms are also expressed, including a secretable form of CTLA-4 (soluble CTLA-4 [sCTLA-4]). The contribution of sCTLA-4 to immune regulation has been less well studied, primarily because it was identified some years after the original description of CTLA-4. Here, we examine how sCTLA-4 might contribute to immune regulation and ask whether it might be a biomarker to inform current CTLA-4 therapies or represent a novel CTLA-4 target for future therapeutics.

Original languageEnglish
Pages (from-to)1073-1084
Number of pages12
JournalImmunotherapy
Volume6
Issue number10
DOIs
Publication statusPublished - Oct 2014

Fingerprint

Immunotherapy
Protein Isoforms
Immune Tolerance
Therapeutics
Autoimmune Diseases
Homeostasis
Biomarkers
Neoplasms
Proteins

Cite this

Targeting the alternatively spliced soluble isoform of CTLA-4 : prospects for immunotherapy? / Ward, Frank J; Dahal, Lekh N; Khanolkar, Rahul C; Shankar, Sucharita P; Barker, Robert N.

In: Immunotherapy, Vol. 6, No. 10, 10.2014, p. 1073-1084.

Research output: Contribution to journalArticle

Ward, Frank J ; Dahal, Lekh N ; Khanolkar, Rahul C ; Shankar, Sucharita P ; Barker, Robert N. / Targeting the alternatively spliced soluble isoform of CTLA-4 : prospects for immunotherapy?. In: Immunotherapy. 2014 ; Vol. 6, No. 10. pp. 1073-1084.
@article{af05b3c570d245c584919276b051d733,
title = "Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy?",
abstract = "CTLA-4 is an inhibitory protein that contributes to immune homeostasis and tolerance, a role that has led to its exploitation as a therapeutic in several clinical settings including cancer and autoimmune disease. Development of CTLA-4 therapies focused largely on the full-length receptor isoform but other CTLA-4 isoforms are also expressed, including a secretable form of CTLA-4 (soluble CTLA-4 [sCTLA-4]). The contribution of sCTLA-4 to immune regulation has been less well studied, primarily because it was identified some years after the original description of CTLA-4. Here, we examine how sCTLA-4 might contribute to immune regulation and ask whether it might be a biomarker to inform current CTLA-4 therapies or represent a novel CTLA-4 target for future therapeutics.",
author = "Ward, {Frank J} and Dahal, {Lekh N} and Khanolkar, {Rahul C} and Shankar, {Sucharita P} and Barker, {Robert N}",
year = "2014",
month = "10",
doi = "10.2217/imt.14.73",
language = "English",
volume = "6",
pages = "1073--1084",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "10",

}

TY - JOUR

T1 - Targeting the alternatively spliced soluble isoform of CTLA-4

T2 - prospects for immunotherapy?

AU - Ward, Frank J

AU - Dahal, Lekh N

AU - Khanolkar, Rahul C

AU - Shankar, Sucharita P

AU - Barker, Robert N

PY - 2014/10

Y1 - 2014/10

N2 - CTLA-4 is an inhibitory protein that contributes to immune homeostasis and tolerance, a role that has led to its exploitation as a therapeutic in several clinical settings including cancer and autoimmune disease. Development of CTLA-4 therapies focused largely on the full-length receptor isoform but other CTLA-4 isoforms are also expressed, including a secretable form of CTLA-4 (soluble CTLA-4 [sCTLA-4]). The contribution of sCTLA-4 to immune regulation has been less well studied, primarily because it was identified some years after the original description of CTLA-4. Here, we examine how sCTLA-4 might contribute to immune regulation and ask whether it might be a biomarker to inform current CTLA-4 therapies or represent a novel CTLA-4 target for future therapeutics.

AB - CTLA-4 is an inhibitory protein that contributes to immune homeostasis and tolerance, a role that has led to its exploitation as a therapeutic in several clinical settings including cancer and autoimmune disease. Development of CTLA-4 therapies focused largely on the full-length receptor isoform but other CTLA-4 isoforms are also expressed, including a secretable form of CTLA-4 (soluble CTLA-4 [sCTLA-4]). The contribution of sCTLA-4 to immune regulation has been less well studied, primarily because it was identified some years after the original description of CTLA-4. Here, we examine how sCTLA-4 might contribute to immune regulation and ask whether it might be a biomarker to inform current CTLA-4 therapies or represent a novel CTLA-4 target for future therapeutics.

U2 - 10.2217/imt.14.73

DO - 10.2217/imt.14.73

M3 - Article

VL - 6

SP - 1073

EP - 1084

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 10

ER -